Zoetis (NYSE:ZTS) Stock Rating Upgraded by Wall Street Zen

Zoetis (NYSE:ZTS) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

Other equities research analysts also recently issued reports about the stock. Morgan Stanley set a $160.00 price target on shares of Zoetis in a report on Thursday, December 18th. HSBC set a $140.00 target price on shares of Zoetis in a research note on Wednesday, December 10th. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. JPMorgan Chase & Co. decreased their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Finally, Bank of America lifted their price objective on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Stock Up 1.1%

ZTS opened at $128.73 on Friday. Zoetis has a 12 month low of $115.25 and a 12 month high of $177.00. The company has a market cap of $54.34 billion, a PE ratio of 21.38, a price-to-earnings-growth ratio of 1.97 and a beta of 0.96. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The company has a 50 day moving average of $125.41 and a 200 day moving average of $134.64.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts expect that Zoetis will post 6.07 EPS for the current year.

Hedge Funds Weigh In On Zoetis

Institutional investors have recently modified their holdings of the company. Halbert Hargrove Global Advisors LLC raised its holdings in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares in the last quarter. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis during the 4th quarter valued at about $25,000. Prosperity Bancshares Inc purchased a new position in shares of Zoetis during the fourth quarter valued at about $25,000. NewSquare Capital LLC increased its position in shares of Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after buying an additional 85 shares during the period. Finally, KERR FINANCIAL PLANNING Corp bought a new position in Zoetis in the third quarter worth about $31,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.